Can Plasma Lipoprotein-Associated PhospholipaseA2 Help Predict DFUs?
Given the recent evidence of biomarker lipoprotein-associated phospholipase A2 (LP-PLA2) in several inflammatory conditions, a poster to be presented at the Symposium on Advanced Wound Care (SAWC) Spring explored the role of LP-PLA2 in predicting diabetic foot ulcers (DFUs).1
The study was a retrospective audit of 212 patients treated between December 2014 and October 2016. Patients were divided into 3 groups: 76 patients with DFUs, 96 patients with diabetes, and 40 control patients. Researchers found higher values of LP-PLA2, fasting plasma glucose, blood pressure, lipid profiles (total cholesterol and triglyceride), degree of atherosclerosis, along with increasing ages and diabetes duration in the DFU group as compared with DM and control groups. The poster notes LP-PLA2 levels were positively correlated with ages, diabetes duration, lipid profiles and increasing severity of DFU while negatively related with high-density lipoprotein cholesterol (HDL-C).
The poster concludes that LP-PLA2 may help to predict the development of DFUs. Authors recommend including LP-PLA2 in the evaluation of routine diabetes foot screening.
Reference
1. Hui Y. The effect level of plasma lipoprotein-associated phospholipaseA2 (LP-PLA2) in patients with diabetic foot ulcers: A retrospective analysis of clinical audit. Presented at Symposium on Advanced Wound Care Spring, April 27–30, 2023.
